XLRS
Brief description of study
ATSN-201 is a gene therapy designed to introduce the functional hRS1 gene to photoreceptors in the eye via subretinal admin using a novel rAAV vector, thereby restoring or attenuating the deterioration of vision in patients with XLRS. Subretinally administered AAV vector-mediated gene augmentation therapy has been shown to be safe in a large number of clinical studies for ocular diseases.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
